Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02188381 · ClinicalTrials.gov registry record
The Role of Gut Microbiota in Hypertension
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 292
- Enrollment target
NCT02188381: Completed study, sponsored by University of Florida.
NCT02188381 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 292 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02188381 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 292 participants
- Enrollment target
Study Summary
Hypertension is the single most prevalent risk factor for heart diseases, heart failure, kidney failure and stroke. About 1 in 3 adults in the United States have hypertension. Approximately 28-30% of hypertensive patients suffer from resistant hypertension (RH). Inflammation has been implicated in the pathogenesis of the hypertension. Additional data suggests the involvement of gut microbiota in host normal cardiovascular functions and pathophysiology. Accumulating evidence demonstrates that antibiotic treatment benefits patients with acute coronary syndromes and reduces the incidence of ischemic cardiovascular events. Even though these studies did not address effects of antibiotic treatment on the gut microbiota, it is possible that gut microbiota could affect neurologic inflammation. Finally, intestinal microbiota has recently been proposed to modulate blood pressure (BP) through production of short-chain fatty acids. In order to investigate this, the investigators hypothesize that gut microbiota is involved in the neuroinflammation-mediated initiation and establishment of RH, and targeting gut microbiota by minocycline would produce beneficial outcomes in RH.
Primary Outcome
Stool samples to analyze the composition of the microbiota, extracted bacterial genomic DNA will be used as a template for PCR reactions targeting the V4-V5 variable regions of the 16S rRNA gene. Amplicons generated from the PCR will be run on the Illumina MiSeq sequencing platform available in our laboratory to profile microbial communities at phylum level.
Interventions
- OTHER Stool Sample and Blood Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2014-07 |
| Est. Completion | 2020-08 |
What the finished NCT02188381 record still lists
NCT02188381 is an observational study that tracks outcomes without assigning an intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Stool Sample and Blood Sample is the first listed.
NCT02188381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02188381 about?
NCT02188381 is a clinical study titled "The Role of Gut Microbiota in Hypertension". Hypertension is the single most prevalent risk factor for heart diseases, heart failure, kidney failure and stroke. About 1 in 3 adults in the United States have hypertension. Approximately 28-30% of hypertensive patients suffer from resistant hypertension (RH). Inflammation has been implicated in t...
What is the current status of trial NCT02188381?
This trial is currently completed. The enrollment target is 292 participants. The study started on 2014-07. Estimated completion is 2020-08.
What interventions are being tested in trial NCT02188381?
The interventions under investigation include: Stool Sample and Blood Sample (OTHER).
Who is sponsoring clinical trial NCT02188381?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia